Summary
Amylin Pharmaceuticals has entered into an agreement with Biocon to jointly develop, commercialize, and manufacture a novel anti-diabetes therapeutic. Amylin will contribute its peptide hormone development expertise, pursuing its renowned phybrid technology. Biocon will help manufacture the compound, utilizing its strong expertise in recombinant microbial expression technology, and will also help bring the drug through preclinical and clinical trials.
Analysis
No details have been disclosed about the identity of the compound, but we suspect that it could be Amylin’s AC-164209, purported to be a peptide hybrid linking a GLP-1 agonist to an Amylin mimetic, or a variation of this compound. Combination therapies have the potential to alleviate the effects of parallel pathway compensation that cannibalize efficacy in monotherapy agents. However—the creation of a new type of compound uniting two peptides into one on a molecular basis would certainly be novel. This is clearly an ambitious endeavor, but it looks as if Amylin is taking smart steps to position itself advantageously through this partnership.
Kelly Close consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
